Gastroenterology Today Spring 2024

CONTENTS
CONTENTS
Gastroenterology Today
Developed to support patient
acceptance 1–3
Shape
• 89.5% of patients found it easy to administer
a torpedo-shaped 1g mesalazine suppository *3,4
* This study was not conducted with Octasa ® 1g suppositories.
Support
• Simple, visual patient materials available to
promote acceptance and adherence 2
Once daily
• For the induction and maintenance of remission
of mild to moderate ulcerative proctitis 1
4 EDITOR’S COMMENT
7 FEATURE The impact of endoscopist performance and patient
factors on distal adenoma detection and colorectal
cancer incidence
21 FEATURE The cost of illness analysis of inflammatory
bowel disease
31 COMPANY NEWS
This issue edited by:
Aaron Bhakta
c/o Media Publishing Company
Greenoaks, Lockhill
Upper Sapey, Worcester, WR6 6XR
ADVERTISING & CIRCULATION:
Media Publishing Company
Greenoaks, Lockhill
Upper Sapey, Worcester, WR6 6XR
Tel: 01886 853715
E: info@mediapublishingcompany.com
www.ambulanceukonline.com
PUBLISHED DATES:
March, June, September and December.
COPYRIGHT:
Media Publishing Company
Greenoaks
Lockhill
Upper Sapey, Worcester, WR6 6XR
Access the Octasa ® 1g suppositories
support materials for your patients
at tillotts.co.uk
COVER STORY
The Viper Hemoclip is designed for endoscopic clip placement within the
gastrointestinal tract for the purpose of hemostasis, defect closure, endoscopic
marking and anchoring.
• Available in 5 sizes (9, 11, 13, 16, 18mm opening)
PUBLISHERS STATEMENT:
The views and opinions expressed in
this issue are not necessarily those of
the Publisher, the Editors or Media
Publishing Company
Next Issue Summer 2024
Designed in the UK by TGDH
• 7mm tail length for visibility
OCTASA 1g Suppositories (mesalazine) - Prescribing Information
Presentation: Suppository containing 1g mesalazine. Indications: Treatment
of acute mild to moderate ulcerative proctitis. Maintenance of remission of
ulcerative proctitis Dosage and administration: Adults and older people:
Acute treatment - one Octasa 1 g Suppository once daily (equivalent to 1
g mesalazine daily) inserted into the rectum. Maintenance treatment - one
Octasa 1 g Suppository once daily (equivalent to 1 g mesalazine daily) inserted
into the rectum. Children: Limited experience and data for use in children.
Method of administration: for rectal use, preferably at bedtime. Duration of
use to be determined by the physician. Contra-indications: Hypersensitivity
to salicylates or any of the excipients, severe impairment of hepatic or renal
function. Warnings and Precautions: Blood tests and urinary status (dip
sticks) should be determined prior to and during treatment, at discretion of
treating physician. Caution in patients with impaired hepatic function. Do not
use in patients with impaired renal function. Consider renal toxicity if renal
function deteriorates during treatment. Cases of nephrolithiasis have been
reported with mesalazine treatment. Ensure adequate fluid intake during
treatment. Monitor patients with pulmonary disease, in particular asthma, very
carefully. Patients with a history of adverse drug reactions to sulphasalazine
should be kept under close medical surveillance on commencement of
therapy, discontinue immediately if acute intolerance reactions occur (e.g.
abdominal cramps, acute abdominal pain, fever, severe headache and rash).
Severe cutaneous adverse reactions (SCARS), including Drug reaction with
eosinophilia and systemic symptoms (DRESS), Stevens-Johnson Syndrome
(SJS) and toxic epidermal necrolysis (TEN) have been reported. Stop treatment
immediately if signs and symptoms of severe skin reactions are seen.
Mesalazine may produce red-brown urine discoloration after contact with
sodium hypochlorite bleach (e.g. in toilets cleaned with sodium hypochlorite
contained in certain bleaches). Interactions: No interaction studies have
been performed. May increase the myelosuppressive effects of azathioprine,
6-mercaptopurine or thioguanine. May decrease the anticoagulant activity
of warfarin. Fertility, pregnancy and lactation: Only to be used during
pregnancy and lactation when the potential benefit outweighs the possible
risk. No effects on fertility have been observed. Adverse reactions: Rare:
Headache, dizziness, myocarditis, pericarditis, abdominal pain, diarrhoea,
flatulence, nausea, vomiting, constipation, photosensitivity, Very rare: Altered
blood counts (aplastic anaemia, agranulocytosis, pancytopenia, neutropenia,
leukopenia, thrombocytopenia), peripheral neuropathy, allergic and fibrotic
lung reactions (including dyspnoea, cough, bronchospasm, alveolitis,
pulmonary eosinophilia, lung infiltration, pneumonitis), acute pancreatitis,
impairment of renal function including acute and chronic interstitial nephritis
and renal insufficiency, alopecia, myalgia, arthraligia, hypersensitivity
reactions (such as allergic exanthema, drug fever, lupus erythematosus
syndrome, pancolitis), changes in liver function parameters (increase in
transaminases and parameters of cholestasis), hepatitis, cholestatic hepatitis,
oligospermia (reversible). Not known: Nephrolithiasis, Drug reaction with
eosinophilia and systemic symptoms, Stevens-Johnson syndrome, and toxic
epidermal necrolysis. Consult the Summary of Product Characteristics in
relation to other adverse reactions. Marketing Authorisation Numbers,
Package Quantities and basic NHS price: PL36633/0011; packs of 10
suppositories (£9.87) and 30 suppositories (£29.62). Legal category: POM.
Marketing Authorisation Holder: Tillotts Pharma UK Ltd, The Larbourne
Suite, The Stables, Wellingore Hall, Wellingore, Lincolnshire, LN5 0HX, UK.
Octasa is a trademark. © 2021 Tillotts Pharma UK Ltd. Further Information
is available from the Marketing Authorisation Holder. Date of preparation of
PI: November 2022
Adverse events should be reported.
Reporting forms and information can be found at
https://yellowcard.mhra.gov.uk. Adverse events
should also be reported to Tillotts Pharma UK Ltd.
(address as above) Tel: 01522 813500.
References
1. Octasa ® 1g Suppositories – Summary of Product Characteristics.
2. Ghosh S, Daperno M. Gastroenterology 2015; 148(4): 701–704.
3. Andus T et al. Inflamm Bowel Dis 2010; 16(11): 1947–1956.
4. Data on file. Tillotts Pharma UK Limited. [Pharmaceutical
Development Information: Octasa ® 1g suppositories] – January 2022.
Date of preparation: December 2022. PU-00987.
Journal: Gastroenterology Today Tillotts: Octasa Range Ad Job no: 04994
Size: 297 x 210 mm Bleed: 3 mm Supply as: HR PDF
• Passes through retroflexed scopes and duodenoscope
How the Assurance Clip Works and Affects Patient Flow and Outcomes
Hemostatic clips are suggested for the treatment of gastrointestinal bleeding and have
been shown to be more effective for the treatment of GI bleeding than other modalities,
such as epinephrine injection alone. 1 Prophylactic endoscopic clip closure of large
mucosal defects following polyp resection has also been demonstrated to reduce the risk
of post procedure bleeding. 2,3
The Assurance hemostatic clip offers 360-degree, one-to-one rotation, ability to reposition
the clip multiple times prior to deployment, opening widths of 9, 11, 13, 16, and 18
millimeters and a retained clip length of 12.5 - 14.5mm millimeters.
GASTROENTEROLOGY TODAY – SPRING 2024
3